Theorem Clinical Research

Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


Panacea Pharmaceuticals engages Accelovance for clinical development

Wednesday, February 11, 2015 12:46 PM

Panacea Pharmaceuticals, based in Gaithersburg, Md., and Accelovance, a CRO headquartered in Rockville, Md., have established a clinical development services agreement to develop and advance Panacea's oncology immunotherapy pipeline. Accelovance will support Panacea's clinical development strategies by offering scientific/medical and regulatory experience, in addition to providing CRO support through project management, clinical monitoring, data management, biostatistics and safety services for Panacea's clinical trials.

More... »

Quest Diagnostics

eClinicalHealth gains approval for Europe’s first fully remote diabetes trial

Wednesday, February 11, 2015 12:44 PM

eClinicalHealth, a Stirling, Scotland-based technology and consulting company providing innovative clinical trial solutions, has announced the Ethical Committee approval of Verkko in Finland—Europe's first remote clinical study to include full electronic informed consent.

More... »


Gilead Sciences, Mobiquity each open new London headquarters

Wednesday, February 11, 2015 12:39 PM

Gilead Sciences, a U.S.-based biotechnology company, is deepening its U.K. presence with a new commercial headquarters in the heart of London from which to grow the company's portfolio, which includes treatments for HIV/AIDS, liver diseases, serious respiratory and cardiovascular diseases and cancer. The company's presence in London will foster closer partnerships with clinicians, patient groups and National Health Service and government organizations, as Gilead continues its efforts to broaden access to innovative medicines.

More... »

Cellular Biomedicine Group, Chinese PLA General Hospital ink agreement

Wednesday, February 11, 2015 12:38 PM

Cellular Biomedicine Group, a Palo Alto, Calif.-based biomedicine company engaged in the development of cellular therapies for degenerative and cancerous diseases, has acquired Chinese PLA General Hospital's (PLAGH, Beijing, also known as 301 Hospital) Chimeric Antigen Receptor T cell (CAR-T) therapy; its recombinant expression vector CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor's (EGFR or HER1) Immuno-Oncology patents (all pending); and phase I/II clinical data of the aforementioned therapies and manufacturing knowledge.

More... »

International GPCR Consortium adds Novo Nordisk and Merck

Wednesday, February 11, 2015 12:34 PM

The GPCR Consortium, an international nonprofit collaboration that comprises academic research institutes in the U.S. and China and major pharma companies around the world, has announced Novo Nordisk and Merck as new members. The companies join AmgenSanofi and Ono in the GPCR Consortium. The research funded by the GPCR Consortium currently is conducted at the Bridge Institute at the University of Southern CaliforniaShanghai Institute of Materia Medica and the iHuman Institute at ShanghaiTech University.

More... »

GlaxoSmithKline acquires GlycoVaxyn for $190M

Wednesday, February 11, 2015 12:32 PM

GlaxoSmithKline has acquired GlycoVaxyn, a specialist vaccine biopharmaceutical company based in Switzerland. Since forming a scientific collaboration in 2012, GSK has held a minority stake in GlycoVaxyn and now has acquired the remaining shares for $190 million in cash to take full ownership of the company.

More... »

BioPharma Services, Scentryphar partner

Wednesday, February 11, 2015 12:30 PM

BioPharma Services (BPSI) has entered into a partnership and joint venture agreement with Scentryphar, a CRO located in Sao Paulo, Brazil. The partnership will support local and global sponsors looking to bring generic and innovative drugs to the Brazilian market by offering one-stop shopping and joint experience in clinical conduct, bioanalysis, data management, statistics and scientific and medical writing.

More... »

ALK, bioCSL partner for allergy tablets

Wednesday, February 11, 2015 12:30 PM

ALK and bioCSL have entered into a long-term partnership covering three ALK products in Australia and New Zealand. The agreement grants bioCSL exclusive rights in Australia and New Zealand to ALK’s sublingual allergy immunotherapy tablets (SLIT-tablets) for house dust mite (HDM) allergy and grass pollen allergy (marketed as Grazax in Europe and Grastek in North America), and its adrenaline auto-injector, Jext. ALK will be responsible for product supply and bioCSL will undertake registration and commercialization of the products.

More... »

Medidata, Garmin partner to optimize trials through mobile health technology

Monday, February 9, 2015 12:25 PM

Medidata, a New York-based global provider of cloud-based solutions for clinical research in life sciences, has formed a strategic collaboration with Garmin International. By integrating Garmin's vívofit activity tracker with the Medidata Clinical Cloud, Medidata is enabling its life sciences customers to make use of mobile health (mHealth) devices with the potential to enhance patient engagement, data quality and operational efficiencies in clinical trials.

More... »

Clinverse expands product suite with introduction of ClinPlan

Monday, February 9, 2015 12:22 PM

Clinverse, a Durham, N.C.-based provider of automated financial management technology solutions for clinical trials, has expanded its suite of products with the addition of ClinPlan, purpose-built software for clinical trial budget management and forecasting.

More... »

AiCure
CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs